Enanta Pharmaceuticals Inc
$ 14.75
9.34%
24 Feb - close price
- Market Cap 391,471,000 USD
- Current Price $ 14.75
- High / Low $ 14.89 / 13.39
- Stock P/E N/A
- Book Value 4.36
- EPS -3.21
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.60 %
- 52 Week High 17.15
- 52 Week Low 4.09
About
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$20.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-09 | 2025-12-01 | 2025-08-11 | 2025-05-12 | 2025-02-10 | 2024-11-25 | 2024-08-05 | 2024-05-06 | 2024-01-26 | 2023-11-20 | 2023-08-07 | 2023-05-08 |
| Reported EPS | -0.42 | -0.87 | -0.85 | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 | -1.58 | -1.33 | -1.86 | -1.79 |
| Estimated EPS | -0.81 | -1.01 | -0.88 | -1.14 | -1.35 | -0.92 | -1.45 | -1.33 | -1.19 | -2.15 | -2.34 | -1.98 |
| Surprise | 0.39 | 0.14 | 0.03 | 0.08 | 0.3 | -0.44 | 0.38 | -0.14 | -0.39 | 0.82 | 0.48 | 0.19 |
| Surprise Percentage | 48.1481% | 13.8614% | 3.4091% | 7.0175% | 22.2222% | -47.8261% | 26.2069% | -10.5263% | -32.7731% | 38.1395% | 20.5128% | 9.596% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.7836 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENTA
2026-02-21 04:31:43
This article provides a detailed financial overview of Enanta Pharmaceuticals Inc (ENTA), including its income statement, balance sheet, cash flow, and key financial ratios. It highlights the company's profitability, growth, leverage, liquidity, and cash flow, revealing a weak overall financial health score of 24/100 based on FY2025 annual data. Key financial metrics such as revenue, EBITDA, free cash flow, net income, and EPS are presented with year-over-year changes and CAGR.
2026-02-20 08:44:00
This article provides an in-depth analysis of Enanta Pharmaceuticals Inc. (ENTA), highlighting a weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies, including long, momentum breakout, and short positions, along with AI-generated signals and risk management parameters. The analysis focuses on resistance and support levels, offering specific entry, target, and stop-loss prices for different trading approaches.
2026-02-13 12:29:07
Enanta Pharmaceuticals (ENTA) reported a Q1 2026 revenue of US$18.6 million and an EPS loss of US$0.42, with a net income loss of US$11.9 million, indicating continued unprofitability despite narrowing losses on a trailing 12-month basis. Analysts emphasize revenue growth as the main upside, but persistent losses and a lower-than-average price-to-sales ratio, coupled with shareholder dilution and insider selling, raise concerns about the company's path to profitability.
2026-02-12 10:58:04
Enanta Pharmaceuticals (NASDAQ:ENTA) exceeded analyst expectations in its first-quarter results, with revenues of US$19m surpassing forecasts by 22% and statutory losses significantly smaller than predicted. Despite these strong results, analysts have not significantly changed their revenue estimates for 2026, though loss per share forecasts have seen a promising decrease. The consensus price target remains at US$19.25, indicating that the improved loss estimates have not yet translated into a long-term positive impact on stock valuation, and the company still faces a forecast revenue decline worse than the industry average.
2026-02-12 10:58:02
Enanta Pharmaceuticals (NASDAQ: ENTA) exceeded revenue expectations in its first quarter, reporting US$19 million, and significantly reduced its statutory loss per share to US$0.42. Analysts have updated their estimates, maintaining a revenue forecast of US$65.3 million for 2026, but notably decreasing the projected loss per share to US$2.35, indicating improved sentiment. Despite the positive adjustments, the company is still expected to experience revenue decline, performing worse than the wider biotech industry.
2026-02-11 02:58:04
HC Wainwright & Co. has reiterated a Buy rating on Enanta Pharma (ENTA) with a price target of $20, maintaining a steady outlook. This decision comes despite varied analyst actions in recent months, highlighting consistent confidence in the biotechnology company's future performance. Analysts' average target price for ENTA is $19.13, suggesting a potential upside of 37.99% from its current price.
